Janux Therapeutics, Inc. (JANX) Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Janux Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount

Janux Therapeutics, Inc. (JANX) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $21.77 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Expense Statement › Income Tax

us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-02-26

• Janux Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $21.77M, a 22.54% increase from fiscal 2024.
• Janux Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $17.76M, a 60.34% increase from fiscal 2023.
• Janux Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was $11.08M, a 35.71% decline from fiscal 2022.
• Janux Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was $17.23M, a 94.27% increase from fiscal 2021.